Neurocentria

Executive Summary

Neurocentria is a late-stage biotechnology company headquartered in San Francisco, California, focused on developing novel small molecule therapies for neurodegenerative and neuropsychiatric disorders. Founded in 2012, the company's platform is built on over 20 years of research demonstrating that intracellular magnesium acts as a critical second messenger for synaptic function and plasticity. This approach targets fundamental mechanisms underlying conditions such as Alzheimer's disease, depression, and other CNS disorders. Neurocentria is currently in Phase 2 clinical development, leveraging its proprietary understanding of magnesium biology to design compounds that modulate synaptic health. The company remains private and has not disclosed detailed financials, but its science addresses a large unmet need in neurology and psychiatry, offering potential for disease-modifying treatments. With a strong scientific foundation and a clear focus on synaptic dysfunction, Neurocentria represents a promising but early-stage investment opportunity in the CNS space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data readout for lead candidate30% success
• H1 2027Initiation of Phase 3 trial in major depressive disorder or Alzheimer's disease25% success
• Q2 2027Strategic partnership or licensing deal for pipeline assets20% success